Benralizumab in severe eosinophilic asthma in real life : confirmed effectiveness and contrasted effect on sputum eosinophilia versus exhaled nitric oxide fraction - PROMISE
Copyright ©The authors 2023..
Background: Randomised controlled trials have shown that benralizumab, an anti-interleukin-5 receptor monoclonal antibody, reduces exacerbations and oral corticosteroid dose and improves asthma control and lung function in severe eosinophilic asthma. The aim of this study was to confirm results of randomised controlled trials in real life in a population of 73 patients with severe eosinophilic asthma treated with benralizumab for at least 12 months.
Methods: Patients underwent careful monitoring of asthma exacerbations, exhaled nitric oxide fraction, lung function, asthma control and quality of life questionnaire responses and sputum induction, and gave a blood sample at baseline, after 6 months and then every year.
Results: We found significant reductions in exacerbations (by 92%, p<0.0001) and oral corticosteroid dose (by 83%, p<0.001) after 6 months that were maintained over time, with 78% of patients able to stop oral corticosteroid therapy. Patients improved their Asthma Control Test (ACT) score (from 11.7±5.1 to 16.9±5.35, p<0.0001), Asthma Control Questionnaire (ACQ) score (from 2.88±1.26 to 1.77±1.32, p<0.0001) and Asthma Quality of Life Questionnaire score (+1.04, p<0.0001) at 6 months and this was maintained during follow-up. Only 35% and 43% of patients reached asthma control according to an ACT score ≥20 and ACQ score <1.5, respectively. We observed stable post-bronchodilation lung function over time and a significant reduction in sputum eosinophil count, with 85% of patients exhibiting sputum eosinophil counts <3% after 6 months (p<0.01) with no effect on exhaled nitric oxide fraction.
Conclusion: In our real-life study, we confirm the results published in randomised controlled trials showing a sharp reduction in exacerbations and oral corticosteroid therapy, an improvement in asthma control and quality of life, and a dramatic reduction in sputum eosinophil count.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
ERJ open research - 9(2023), 6 vom: 15. Nov. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Schleich, Florence [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 01.12.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1183/23120541.00383-2023 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365117102 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365117102 | ||
| 003 | DE-627 | ||
| 005 | 20231226101005.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1183/23120541.00383-2023 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1216.xml |
| 035 | |a (DE-627)NLM365117102 | ||
| 035 | |a (NLM)38020567 | ||
| 035 | |a (PII)00383-2023 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Schleich, Florence |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Benralizumab in severe eosinophilic asthma in real life |b confirmed effectiveness and contrasted effect on sputum eosinophilia versus exhaled nitric oxide fraction - PROMISE |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 01.12.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright ©The authors 2023. | ||
| 520 | |a Background: Randomised controlled trials have shown that benralizumab, an anti-interleukin-5 receptor monoclonal antibody, reduces exacerbations and oral corticosteroid dose and improves asthma control and lung function in severe eosinophilic asthma. The aim of this study was to confirm results of randomised controlled trials in real life in a population of 73 patients with severe eosinophilic asthma treated with benralizumab for at least 12 months | ||
| 520 | |a Methods: Patients underwent careful monitoring of asthma exacerbations, exhaled nitric oxide fraction, lung function, asthma control and quality of life questionnaire responses and sputum induction, and gave a blood sample at baseline, after 6 months and then every year | ||
| 520 | |a Results: We found significant reductions in exacerbations (by 92%, p<0.0001) and oral corticosteroid dose (by 83%, p<0.001) after 6 months that were maintained over time, with 78% of patients able to stop oral corticosteroid therapy. Patients improved their Asthma Control Test (ACT) score (from 11.7±5.1 to 16.9±5.35, p<0.0001), Asthma Control Questionnaire (ACQ) score (from 2.88±1.26 to 1.77±1.32, p<0.0001) and Asthma Quality of Life Questionnaire score (+1.04, p<0.0001) at 6 months and this was maintained during follow-up. Only 35% and 43% of patients reached asthma control according to an ACT score ≥20 and ACQ score <1.5, respectively. We observed stable post-bronchodilation lung function over time and a significant reduction in sputum eosinophil count, with 85% of patients exhibiting sputum eosinophil counts <3% after 6 months (p<0.01) with no effect on exhaled nitric oxide fraction | ||
| 520 | |a Conclusion: In our real-life study, we confirm the results published in randomised controlled trials showing a sharp reduction in exacerbations and oral corticosteroid therapy, an improvement in asthma control and quality of life, and a dramatic reduction in sputum eosinophil count | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Moermans, Catherine |e verfasserin |4 aut | |
| 700 | 1 | |a Seidel, Laurence |e verfasserin |4 aut | |
| 700 | 1 | |a Kempeneers, Céline |e verfasserin |4 aut | |
| 700 | 1 | |a Louis, Gilles |e verfasserin |4 aut | |
| 700 | 1 | |a Rogister, Florence |e verfasserin |4 aut | |
| 700 | 1 | |a Tombu, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Pottier, Laurence |e verfasserin |4 aut | |
| 700 | 1 | |a Poirrier, Anne-Lise |e verfasserin |4 aut | |
| 700 | 1 | |a Ziant, Stéphanie |e verfasserin |4 aut | |
| 700 | 1 | |a Henket, Monique |e verfasserin |4 aut | |
| 700 | 1 | |a Sanchez, Carole |e verfasserin |4 aut | |
| 700 | 1 | |a Paulus, Virginie |e verfasserin |4 aut | |
| 700 | 1 | |a Guissard, Françoise |e verfasserin |4 aut | |
| 700 | 1 | |a Donneau, Anne-Françoise |e verfasserin |4 aut | |
| 700 | 1 | |a Louis, Renaud |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ERJ open research |d 2015 |g 9(2023), 6 vom: 15. Nov. |w (DE-627)NLM255762003 |x 2312-0541 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2023 |g number:6 |g day:15 |g month:11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1183/23120541.00383-2023 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2023 |e 6 |b 15 |c 11 | ||